Literature DB >> 2469499

Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes.

P Valent1, L K Ashman, W Hinterberger, F Eckersberger, O Majdic, K Lechner, P Bettelheim.   

Abstract

The immunologic surface marker profile of human mast cells (MCs) was established using a combined toluidine/immunofluorescence staining procedure [49 monoclonal antibodies (MoAbs) tested]. Ascites (n = 9) MCs as well as enzymatically dispersed MCs from all organs tested (lung n = 11, skin n = 7, intestinum n = 10) exhibited an identical marker profile. MCs were recognized by MoAbs clustered as CD9 (anti-gp24), CD33 (anti-gp67), and CD45 (anti-gp220) as well as by MoAbs directed against membrane-bound IgE. MoAB YB5B8 (anti-gp145) selectively recognized MCs. Most significantly, however, MCs were stained by MoAbs MAX1 (anti-gp65), MAX3 (anti-gp68), MAX11 (anti-gp65), and MAX24 (anti-gp65). These antibodies bind to surface membrane antigens associated with a late stage of monocyte/macrophage differentiation. Thus, our results provide definite evidence that MCs share surface membrane markers with mononuclear phagocytes. In contrast, MCs are stained neither by lymphatic markers (CD1-8, 10, 19-24) nor by myelomonocytic markers (CD11-17). MCs also lack the interleukin-2 (IL-2) receptor (CD25), the T10 antigen (CD38), and most of the myelocytic markers expressed on peripheral blood (PB) basophils. Thus, MCs displayed a unique phenotype within the hematopoietic system. This new approach enabled us to enrich human lung MCs to a purity greater than 95% by means of negative selection with complement-mediated cell lysis. Purified MCs were subsequently stained with MoAbs and analyzed by flow cytometry, which confirmed the results obtained from the double-staining experiments. We next examined cultured metachromatic cells derived from bone marrow (BM) and peripheral blood colony-forming units (CFU). These metachromatic cells previously could not be classified by morphologic criteria alone and have therefore been termed basophil-like/MC-like cells. In this study, toluidine blue-positive cells obtained from either pooled multipotential colonies (day 14-CFU-GEM) or pooled myelocytic colonies (day 16/17-CFU-GM/G/M) were recognized by MoAbs MY7 (CD13), VIM12 (CD11b), and VIM2, as well as by an anti-IgE MoAb, after preincubation with IgE. In contrast, CFU-derived metachromatic cells were not stained by MoAb YB5B8. This marker profile corresponds to the immunologic phenotype of blood basophils and excluded a detectable formation of mature MCs in colonies derived from cultured hematopoietic stem cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469499

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Use of monoclonal antibody KP1 for identifying normal and neoplastic human mast cells.

Authors:  H P Horny; G Schaumburg-Lever; S Bolz; M L Geerts; E Kaiserling
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

2.  Differential expression of cell surface integrins on human mast cells and human basophils.

Authors:  W R Sperr; H Agis; K Czerwenka; W Klepetko; E Kubista; G Boltz-Nitulescu; K Lechner; P Valent
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

3.  Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration.

Authors:  A Orfao; L Escribano; J Villarrubia; J L Velasco; C Cerveró; J Ciudad; J L Navarro; J F San Miguel
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

4.  Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells.

Authors:  K Hamann; J Grabbe; P Welker; N Haas; B Algermissen; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

5.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Authors:  Barbara Peter; Karoline V Gleixner; Sabine Cerny-Reiterer; Harald Herrmann; Viviane Winter; Emir Hadzijusufovic; Veronika Ferenc; Karina Schuch; Irina Mirkina; Hans-Peter Horny; Winfried F Pickl; Leonhard Müllauer; Michael Willmann; Peter Valent
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

6.  Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Authors:  Gregor Hoermann; Sabine Cerny-Reiterer; Andrea Perné; Miriam Klauser; Konrad Hoetzenecker; Katharina Klein; Leonhard Müllauer; Marion Gröger; Sebastian M B Nijman; Walter Klepetko; Peter Valent; Matthias Mayerhofer
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

Review 7.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

8.  Phenotypic characterization of stem cell factor-dependent human foetal liver-derived mast cells.

Authors:  G Nilsson; K Forsberg; M P Bodger; L K Ashman; K M Zsebo; T Ishizaka; A M Irani; L B Schwartz
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

9.  PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule.

Authors:  B Falini; L Flenghi; S Pileri; M Gambacorta; B Bigerna; H Durkop; F Eitelbach; J Thiele; R Pacini; A Cavaliere
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

10.  Differential response of human basophils and mast cells to recombinant chemokines.

Authors:  W Füreder; H Agis; H Semper; F Keil; U Maier; M R Müller; K Czerwenka; H Höfler; K Lechner; P Valent
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.